These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27501851)

  • 1. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial.
    Okada K; Kawai M; Hirono S; Satoi S; Yanagimoto H; Ioka T; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):719-26. PubMed ID: 27501851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
    Janssen QP; Buettner S; Suker M; Beumer BR; Addeo P; Bachellier P; Bahary N; Bekaii-Saab T; Bali MA; Besselink MG; Boone BA; Chau I; Clarke S; Dillhoff M; El-Rayes BF; Frakes JM; Grose D; Hosein PJ; Jamieson NB; Javed AA; Khan K; Kim KP; Kim SC; Kim SS; Ko AH; Lacy J; Margonis GA; McCarter MD; McKay CJ; Mellon EA; Moorcraft SY; Okada KI; Paniccia A; Parikh PJ; Peters NA; Rabl H; Samra J; Tinchon C; van Tienhoven G; van Veldhuisen E; Wang-Gillam A; Weiss MJ; Wilmink JW; Yamaue H; Homs MYV; van Eijck CHJ; Katz MHG; Groot Koerkamp B
    J Natl Cancer Inst; 2019 Aug; 111(8):782-794. PubMed ID: 31086963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
    Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
    Pancreatology; 2020 Sep; 20(6):1131-1138. PubMed ID: 32739267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
    Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
    Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
    Okada KI; Hirono S; Kawai M; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Hayami S; Yamaue H
    Anticancer Res; 2017 Feb; 37(2):853-858. PubMed ID: 28179342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer.
    Okano N; Matsuki R; Toki M; Gondo K; Ochiai K; Watanabe S; Tateishi H; Kogure M; Suzuki Y; Sugiyama M; Nagashima F; Shibahara J; Sakamoto Y; Furuse J
    Intern Med; 2023 Feb; 62(3):327-334. PubMed ID: 35793961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
    Polish A; Joseph NE; Marsh RW
    Am J Clin Oncol; 2019 Oct; 42(10):761-766. PubMed ID: 31569128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
    Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
    Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
    Han S; Choi SH; Choi DW; Heo JS; Han IW; Park DJ; Ryu Y
    Minerva Chir; 2020 Feb; 75(1):15-24. PubMed ID: 31115240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.
    Li X; Guo C; Li Q; Wei S; Zhang Q; Chen Y; Shen Y; Ma T; Li G; Gao S; Que R; Lou J; Yu R; Yuan Y; Wei Q; Huang P; Liang T; Bai X
    Oncologist; 2019 Mar; 24(3):301-e93. PubMed ID: 30459238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
    Huang X; Knoble JL; Zeng M; Aguila FN; Patel T; Chambers LW; Hu H; Liu H
    PLoS One; 2016; 11(12):e0166606. PubMed ID: 27935952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
    J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
    Golan T; Barenboim A; Lahat G; Nachmany I; Goykhman Y; Shacham-Shmueli E; Halpern N; Brazowski E; Geva R; Wolf I; Goldes Y; Ben-Haim M; Klausner JM; Lubezky N
    Ann Surg Oncol; 2020 Oct; 27(10):3963-3970. PubMed ID: 32314163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
    Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
    BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.